ERT, a global data and technology company that captures critical endpoint data while minimizing uncertainty and risk in clinical trials, today announced a Virtual Visit solution that enables the continuation of clinical trials during and after current global stay-at-home mandates.

As a result of COVID-19, many clinical trials have been delayed as healthcare providers focus their efforts on patients who require urgent care, which limits clinical trial patients’ access to investigative sites for routine visits. In order to keep their studies on track, clinical trial sponsors and CROs need innovative solutions that enable investigative site personnel and patients to interact with each other, regardless of their physical location (often referred to as TeleHealth).

ERT’s Virtual Visit solution enables at-home consultations between patients and investigative site personnel via a seamless, dedicated, secure app or web interface. The offering allows patients to consult with their clinicians safely from home, simplifying their participation in clinical trials and enabling researchers to continue collecting the important safety and efficacy data needed to support their development objectives. The solution complements ERT’s suite of safety and efficacy data capture solutions, improving patient engagement throughout ongoing and new clinical trials.

“We're pleased to offer another significant capability in a series of revolutionary virtual trial solutions to support our customers as they address the challenges presented by COVID-19,” said Matthew McCarty, Vice President, Digital Patient at ERT. “Our research indicates that nearly 80% of the industry is shifting to virtual trial solutions during this unprecedented time and we remain committed to delivering the dynamic tools they need to continue their important, life-saving research.”

Click here to learn more about ERT’s Virtual Visit solution.

About ERT
ERT is a global data and technology company that minimizes uncertainty and risk in clinical trials so that its customers can move ahead with confidence. With nearly 50 years of clinical and therapeutic experience, ERT balances knowledge of what works with a vision for what’s next, so it can adapt without compromising standards.

Powered by the company’s EXPERT^® technology platform, ERT’s solutions enhance trial oversight, enable site optimization, increase patient engagement and measure the efficacy of new clinical treatments while ensuring patient safety. In 2019, 75% of all FDA drug approvals came from ERT-supported studies. Pharma companies, biotechs and CROs have relied on ERT solutions across 15,000 studies, spanning more than four million patients to date. By identifying trial risks before they become problems, ERT enables customers to bring clinical treatments to patients quickly ─ and with confidence.

 For more information, go to ert.com or follow us on LinkedIn and Twitter.